Could a common diabetes drug ease knee arthritis pain?

NCT ID NCT06231758

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether adding metformin, a diabetes drug, to standard pain relief (celecoxib) can reduce pain and improve knee function in people with knee osteoarthritis. The study will enroll 70 adults aged 30-60 with moderate knee arthritis. Researchers will measure pain changes using a standard pain scale and the WOMAC osteoarthritis index.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Metformin (a diabetes drug) combined with Celecoxib (an anti-inflammatory painkiller)

What this could lead to

If it works, this could offer a new, affordable way to better manage knee osteoarthritis pain and slow joint damage.

What could go wrong

This is a small, early-phase trial with only 70 participants. Metformin is not proven for arthritis yet, and results may not apply to everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mostafa Bahaa

    RECRUITING

    Damietta, New Damietta, 34518, Egypt

    Contact Phone: •••-•••-•••• Email: •••••@•••••